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Delay in the diagnosis of pulmonary tuberculosis, London,
1998-2000: analysis of surveillance data
Alison Rodger, Shabbar Jaffar, Stuart Paynter, Andrew Hayward, Jacqui Carless, Helen Maguire
Noted cases of tuberculosis each year have doubled in
London since 1987. In 2000, 12.9 cases per 100 000
population in England and Wales were recorded com-
pared with 40.3 cases in London.1 A delay in the diag-
nosis of tuberculosis increases the risk of poor clinical
outcome—including death and transmission of tuber-
culosis.2 3 Understanding which factors influence this
delay is crucial for controlling tuberculosis.
Only one small study has previously investigated
delays in the diagnosis of pulmonary tuberculosis in
the United Kingdom.4 Using surveillance data from
London, we estimated the delays in diagnosis of tuber-
culosis and investigated the factors independently
associated with delays.
Methods and results
We analysed surveillance data collected by doctors
(1999-2000) and an anonymised national survey (1998)
for cases of tuberculosis in London from 1998 to 2000.
We calculated the delay in diagnosis as the number of
days between the onset of symptoms and diagnosis or
the start of treatment (which were on the same day in
cases with both recorded). Delay was characterised as
greater than the median or at or less than the median.
We used unconditional logistic regression to investigate
factors that were independently associated with delay.
A total of 1355 patients had a positive result in
smear tests of pulmonary sputum; we give results for
853 (63%) about whom data on the time between onset
of symptoms and diagnosis had been recorded.
Patients with data and those without were similar for
age, sex, and ethnic group.
The median age was 34 (interquartile range 26-51)
years; 505/849 (60%) of patients were men. A total of
263/842 (31%) patients were white and 267/842 (32%)
were black; 542/782 (69%) of patients were born outside
the United Kingdom. Median delay was 49 (14-103)
days.Univariate analysis showed that factors significantly
associated with delay of longer than 49 days until
diagnosis or treatment were age, birthplace (United
Kingdom or overseas), sex, and ethnic group (table). The
geometric mean delay in days were 72 (95% confidence
interval 63 to 80) among white patients and 43 (39 to
45) among all other ethnic groups, 72 (66 to 77) among
women and 61 (56 to 65) among men, and 64 (55 to 74)
among those aged >40 years and 45 (40 to 51) among
patients aged < 40 years. Among patients not born in
the United Kingdom, time since entry was significantly
positively associated with delay being greater than the
median (P=0.01). In multivariate analysis, delays were
more likely for white patients (adjusted odds ratio 1.67
(1.2 to 2.5); P=0.01) and women (1.42 (1.1 to 1.9);
P=0.01). Age and birth place were not independently
associated with delay.
Comment
Delay between the onset of symptoms of pulmonary
tuberculosis and diagnosis or treatment (median 49
days) was more common for white people and for
women. This median delay is similar to findings in other
Odds ratios for delay in the diagnosis of tuberculosis in patients testing positive for tuberculosis in smear tests, London, 1998 to
2000*
Characteristic No (n=853)†
No (%) with
longer than
median delay
Unadjusted odds ratio Adjusted odds ratio‡
Value 95% CI P value Value 95% CI P value
Sex:
Male 509 244 (48) 1 —
0.027
1 —
0.01
Female 344 196 (57) 1.37 1.05 to 1.82 1.46 1.1 to 1.9
Age (years):
<40 511 245 (48) 1 —
0.009
1 —
0.11
≥40 337 192 (57) 1.46 1.09 to 1.95 1.18 0.87 to 1.62
Ethnic group:
White 263 163 (62) 1 —
0.021
1 —
0.03
Black 267 112 (42) 0.44 0.30 to 0.63 0.52 0.33 to 0.80
Indian subcontinent 224 114 (51) 0.61 0.42 to 0.89 0.64 0.42 to 0.99
Other 88 43 (49) 0.62 0.37 to 1.02 0.73 0.41 to 1.29
Birthplace:
United Kingdom 240 146 (61) 1 —
0.0005
1 —
0.32
Other 542 255 (47) 0.58 0.43 to 0.79 0.82 0.56 to 1.21
Time since entry to United Kingdom§:
<2 years 49 16 (33) 1 —
0.010
— —
—2-5 years 180 79 (44) 1.73 0.87 to 3.43 — —
>5 years 204 112 (55) 2.65 1.34 to 5.25 — —
*Associations between categorical data were assessed using 2 or Fisher’s exact tests, as appropriate. Continuous data were compared using t tests if approximately
normally distributed or otherwise using the Wilcoxon test.
†Data are missing for sex in 0, for age in 5, for ethnic group in 11, for birth place in 71, and year of entry to the United Kingdom in 109 cases.
‡Adjusted for sex, age, ethnic group, and whether the patient was born in the United Kingdom.
§Not investigated in the multivariate model.
Papers
Infectious Disease
Epidemiology Unit,
London School of
Hygiene and
Tropical Medicine,
London
WC1E 7HT
Alison Rodger
specialist registrar
Shabbar Jaffar
senior lecturer
European Centre
on the Health of
Societies in
Transition, London
School of Hygiene
and Tropical
Medicine
Stuart Paynter
specialist registrar
UCL Centre for
Infectious Disease
Epidemiology,
Department of
Primary Care and
Population
Sciences, Royal Free
and University
College Medical
School, London
NW3 2PF
Andrew Hayward
senior lecturer
Communicable
Disease
Surveillance Centre,
London Regional
Unit, London,
W2 3QR
Jacqui Carless
information officer
(TB)
Helen Maguire
consultant regional
epidemiologist
Correspondence to:
A Rodger
alison.rodger@
lshtm.ac.uk
BMJ 2003;326:909–10
909BMJ VOLUME 326 26 APRIL 2003 bmj.com
large cities in industrialised nations.5 This might be
because tuberculosis may be suspected and investigated
more readily among men or black or Asian people.
Our study was limited by the amount of missing
surveillance data. It was also impossible to determine
the relative contribution of patient and healthcare pro-
vider to the total delay. Potential confounders—for
example, coinfection with HIV or the accuracy of the
data among patients whose first language was not
English—were not taken account of.
Recent campaigns have tried to raise awareness of
tuberculosis, particularly among ethnic minority groups.
Our data suggest that campaigns also need to be
targeted at white people, who comprise a third of cases.
We thank John Watson for access to the anonymised data from
the national tuberculosis survey 1998.
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Drug points
Erythromelalgia induced by possible calcium
channel blockade by ciclosporin
Gurvinder P Thami, Mala Bhalla
Erythromelalgia, a symptom complex of painful inflam-
matory vasodilatation of extremities, is usually idiopathic
or due to thrombocythaemia. It has often been regarded
as inverse Raynaud’s phenomenon, rarely induced by cal-
cium channel blockers.1 We report a case of erythromelal-
gia induced by ciclosporin.
A 37 year old man had been taking ciclosporin 75 mg
twice daily for psoriasis vulgaris for four weeks when he
developed marked erythema, oedema, and tenderness
over fingers and toes. Symptoms increased with warmth
and were relieved partially with cold compresses. His full
blood count, serum biochemistry, urine analysis, and
collagen profile were normal. Erythromelalgia induced by
ciclosporin was considered, and the drug was withdrawn.
Lesions regressed within a week but recurred when
ciclosporin was restarted. No recurrence was observed at
one year follow up.
Erythromelalgia is a multifactorial peripheral vascular
phenomenon akin to sympathectomy, with attenuation of
vasomotor tone probably mediated through vasoactive
substances and drugs such as nifedipine, nicardipine, vera-
pamil, and bromocriptine.1
Ciclosporin, a calcineurin antagonist, acts by inhibit-
ing calcium-calmodulin signalling systems of target cells in
a way similar to calcium channel blockers.2 It binds to cal-
modulin, with a consequent inhibition of dephosphoryla-
tion of calmodulin induced kinases and other calmodulin
dependent intracellular activities.3 Ciclosporin also affects
the calmodulin regulated activity of the actomyosin
complex of smooth muscle of peripheral vessels, which
leads to vasodilatation. In this way, ciclosporin has also
been observed to potentiate the peripheral vasodialatory
effects of calcium channel blockers.4
The erythromelalgia in this patient may have been the
result of ciclosporin acting in a similar way to calcium
channel blockers. Though burning sensation of the hands
and feet has been mentioned as an adverse effect in the
product leaflet of ciclosporin (Panimun Bioral, Panacea
Biotec) and a leg pain syndrome has been described, an
erythromelalgia-like effect has not been reported.5 This
possible vasoactive effect of ciclosporin needs further
evaluation given that vasoactive peptides may be present
in psoriasis.
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Corrections and clarifications
Mark Twain on evidence based practice
This Endpiece attributed the quotation “It ain’t
what people don’t know that hurts them it’s what
they know that ain’t so” to Mark Twain (25 January,
p 211). However, a reader has corrected us,
confirming that this quotation is attributable not to
Mark Twain but to Josh Billings (and in support has
cited various sources, including the Penguin
Dictionary of Modern Humorous Quotations, Penguin,
1987). A trawl of the web, however, has revealed
that people often get it wrong, attributing the
quotation in question not to Josh Billings but to
Mark Twain—or to Will Rogers or Herbert Stein
(or possibly others). The quotation always appears
in slightly different forms; indeed, the one cited in
the Penguin dictionary is not exactly the same as
the one we published.
Filler: He died “peacefully” at home
Although editors are aware of the dangers of
confusing words that differ in spelling by only one
letter, there is always a danger that the wrong word
will slip through. Unfortunately, this is what
happened in this account by David Veale of the
death of his father—we used the word prostrate,
rather than prostate (12 April, p 792).
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